Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MREO Mereo BioPharma Group	$2.59 +2.8%	$2.34	$1.58 ▼ $5.02	$411.81M	0.71	1.10 million shs	806,147 shs
PRTC PureTech Health	$17.26 -1.4%	$17.42	$13.30 ▼ $32.98	$414.57M	1.12	4,675 shs	1,114 shs
RAPP Rapport Therapeutics	$11.45 +3.5%	$9.93	$6.43 ▼ $29.74	$417.90M	N/A	177,422 shs	98,157 shs
SLN Silence Therapeutics	$3.70 +8.8%	$3.50	$1.97 ▼ $24.38	$110.74M	1.25	295,518 shs	189,136 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MREO Mereo BioPharma Group	-3.45%	+0.80%	+9.57%	-13.99%	-8.70%
PRTC PureTech Health	+2.21%	+0.66%	-9.51%	-7.27%	-38.60%
RAPP Rapport Therapeutics	-2.81%	-4.24%	+10.05%	-29.24%	+1,105,999,900.00%
SLN Silence Therapeutics	-2.86%	+11.48%	-1.16%	-35.11%	-84.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MREO Mereo BioPharma Group	2.3344 of 5 stars	3.6	2.0	3.7	1.7	0.0
PRTC PureTech Health	2.0075 of 5 stars	3.8	3.0	2.7	0.0	0.0
RAPP Rapport Therapeutics	2.4438 of 5 stars	3.5	2.0	3.2	1.7	0.6
SLN Silence Therapeutics	2.3387 of 5 stars	3.4	1.0	4.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MREO Mereo BioPharma Group	3.25	Buy	$7.71	197.85% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	160.72% Upside
RAPP Rapport Therapeutics	3.00	Buy	$32.67	185.30% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$40.67	999.10% Upside

Current Analyst Ratings Breakdown

Latest SLN, RAPP, MREO, and PRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$28.00
4/8/2025	RAPP Rapport Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform
3/27/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
3/26/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/18/2025	MREO Mereo BioPharma Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $7.00
3/7/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/5/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$49.00 ➝ $45.00
3/4/2025	SLN Silence Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$67.00 ➝ $25.00
3/4/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$6.00 ➝ $4.00
2/11/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MREO Mereo BioPharma Group	$1M	411.81	N/A	N/A	$0.36 per share	7.19
PRTC PureTech Health	$3.33M	124.49	N/A	N/A	$16.94 per share	1.02
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	$43.26M	2.56	N/A	N/A	$0.71 per share	5.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MREO Mereo BioPharma Group	-$29.47M	-$0.06	N/A	N/A	N/A	N/A	N/A	N/A	5/21/2025 (Estimated)
PRTC PureTech Health	-$65.70M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	4/30/2025 (Estimated)
RAPP Rapport Therapeutics	-$34.79M	-$13.84	N/A	N/A	N/A	N/A	N/A	N/A	6/2/2025 (Estimated)
SLN Silence Therapeutics	-$53.82M	-$0.95	N/A	N/A	N/A	-342.00%	-62.81%	-33.89%	5/15/2025 (Estimated)

Latest SLN, RAPP, MREO, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	N/A	N/A	N/A	$3.58 million	N/A
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MREO Mereo BioPharma Group	N/A	6.10	6.10
PRTC PureTech Health	N/A	3.68	N/A
RAPP Rapport Therapeutics	N/A	45.91	45.91
SLN Silence Therapeutics	N/A	9.31	9.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MREO Mereo BioPharma Group	62.83%
PRTC PureTech Health	0.04%
RAPP Rapport Therapeutics	N/A
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
MREO Mereo BioPharma Group	5.50%
PRTC PureTech Health	5.30%
RAPP Rapport Therapeutics	N/A
SLN Silence Therapeutics	2.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MREO Mereo BioPharma Group	40	159.00 million	148.74 million	Optionable
PRTC PureTech Health	100	24.02 million	22.67 million	Not Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	N/A	N/A
SLN Silence Therapeutics	100	29.93 million	N/A	Not Optionable

SLN, RAPP, MREO, and PRTC Headlines

Recent News About These Companies

Silence Therapeutics plc (NASDAQ:SLN) Stock Holdings Increased by Nantahala Capital Management LLC

April 30 at 8:14 AM | marketbeat.com

Boothbay Fund Management LLC Has $2.42 Million Position in Silence Therapeutics plc (NASDAQ:SLN)

April 30 at 6:21 AM | marketbeat.com

Marshall Wace LLP Purchases 320,472 Shares of Silence Therapeutics plc (NASDAQ:SLN)

April 28 at 4:11 AM | marketbeat.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics plc (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by Brokerages

April 20, 2025 | marketbeat.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

March 4, 2025 | zacks.com

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2025 | uk.finance.yahoo.com

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

February 28, 2025 | seekingalpha.com

Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

February 28, 2025 | biospace.com

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025 | businesswire.com

Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation

February 11, 2025 | msn.com

Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints

February 11, 2025 | seekingalpha.com

Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data

February 11, 2025 | markets.businessinsider.com

Silence Therapeutics initiated with a Sell at Goldman Sachs

February 11, 2025 | markets.businessinsider.com

Goldman Sachs cuts Silence Therapeutics stock rating to Sell

February 11, 2025 | msn.com

(SLN) Investment Analysis

January 17, 2025 | news.stocktradersdaily.com

(SLN) On The My Stocks Page

January 7, 2025 | news.stocktradersdaily.com

Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now

December 18, 2024 | insidermonkey.com

How the (SLN) price action is used to our Advantage

December 17, 2024 | news.stocktradersdaily.com

Silence Therapeutics announces additional results from SANRECO study

December 10, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
Hidden Gems: 3 Quiet Stocks With Loud Potential
By Nathan Reiff | April 23, 2025
View Hidden Gems: 3 Quiet Stocks With Loud Potential

SLN, RAPP, MREO, and PRTC Company Descriptions

Mereo BioPharma Group NASDAQ:MREO

$2.59 +0.07 (+2.78%)

As of 04:00 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

PureTech Health NASDAQ:PRTC

$17.26 -0.24 (-1.37%)

As of 03:48 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Rapport Therapeutics NASDAQ:RAPP

$11.45 +0.39 (+3.53%)

As of 04:00 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Silence Therapeutics NASDAQ:SLN

$3.70 +0.30 (+8.82%)

As of 04:00 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time